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In most cases gastro-enteropancreatic neuroendocrine tumors grow slowly. Interferon-a and somatostatin
analogs have shown symptomatic, biochemical, and, in a minority of cases, antiproliferative activity.
Generally, they are proposed as single-agent therapy. However, based on in vitro and in vivo evidence, the
combined use of these drugs was proposed in several non-randomized trials, indicating that there is an
additive effect of the combination. Nevertheless, the three randomized trials published so far did not show
a statistically significant survival benefit for the combination compared to the same agents alone, even though
an advantage for the combination came out in all three studies. On the other hand, data from non-randomized
trials would justify the sequential use of the two drugs or the combination after progression on single agent
therapy. Therefore, at present the up-front combined use of interferon-a and somatostatin analog is not
justified, whereas it could be indicated after progression to single-agent therapy. Further larger, international,
prospective, randomized, multicentric clinical trials studying homogeneous populations would be necessary
to give a final answer, but the rarity and heterogeneity of this malignancy does not assure that it will be
possible.
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introduction
Neuroendocrine tumors (NETs) represent a very heterogeneous
and rare category of neoplasms, accounting for only 0.5% of
all malignancies. Gastroenteropancreatic (GEP) NETs are the
most common group [1], with gastrointestinal (GI) primary
tumors being much more frequent than pancreatic ones.
Ileum has the highest incidence.
These neoplasms are named functioning when they show
a clinical syndrome related to hormones hypersecreted by the
tumor, and non-functioning when no specific syndrome is
present whereas symptoms are only related to the ‘mass effect’
caused by the tumor growth. Among the functioning tumors the
main clinical entities are: the carcinoid syndrome [2], the
hypoglycemia syndrome [3], the Zollinger-Ellison syndrome
[4], the WDHA (watery diarrhea, hypokaliemia, achlorydria)
syndrome [5], and the glucagonoma syndrome [6].
The typical carcinoid syndrome can be found in less than
20% of carcinoids, particularly mid-gut primary and liver
metastases [7]. In rare cases an atypical carcinoid syndrome can
be present [8], particularly in patients with foregut carcinoid
tumors. About 30–40% of pancreatic-NET patients present
without hormone-related symptoms; in the other cases
syndromes related to a specific secreted hormone are
present [9].
Global prognosis of NET patients is relatively favorable, with
a five-year survival rate of around 70%, including all sites, stages
and kinds of tumor. Local and distant metastases may allow
a considerable 5-year survival rate of 72 and 39%, respectively.
Among GEP NETs, rectal and appendiceal tumors are associated
with the best survival [1].
According to the WHO classification, by Solcia and
co-workers, published in 2000 [10], GEP NETs are distinguished
in three types: well-differentiated tumors or carcinoids,
well-differentiated carcinomas or malignant carcinoids,
and poorly-differentiated carcinomas or small-cell carcinomas.
The old classification, including foregut, midgut and hindgut
carcinoids [11], should be considered obsolete by now.
somatostatin analogs
background
Somatostatin (sst) was discovered by Brazeau et al. [12] in 1973
at the Salk Institute in La Jolla, California. It is expressed in
many tissues and organs of our body, including the central
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nervous system and gastrointestinal tract, and acts as
a neurotransmitter, or exocrine and endocrine glands, GI
motility, and vasotone regulator, depending upon its target
tissue. Several forms exist, but a 14 and 28 amino acids
cyclopeptide represent the most important forms. Somatostatin
exerts its action via five specific receptors, named sstr 1–5 [13].
Because of its short half-life (< 3 min), sst was inconvenient for
clinical use, and therefore analogs were developed at the
beginning of the 1980s [14]. Two of them, octreotide and
lanreotide, are regularly used in clinics [15]. They have a 1–2-h
half-life and they can be administered subcutaneously,
intravenously and intramuscularly. Native sst binds to all five
subtypes of receptors (r), whereas the two analogs bind in
particular to subtype 2, and with a somewhat lower affinity to
the sstr-3 and sstr-5 subtypes. Somatostatin analogs can control
hypersecretion in NETs that express sst-receptors. In addition,
these agents may also exert some anti-proliferative activity [16].
Symptomatic and biochemical activities of sst-analogs are, by
now, well recognized in small-bowel NETs, with a response rate
of roughly 90% and 70% respectively [17, 18]. Similar results
were reported in pancreatic endocrine tumors, with a lower
activity in insulinoma, because in 50% of cases sst2 receptors are
missing [19].
Tumour shrinkage was demonstrated in a very small
percentage of cases with standard dose [20–23]. However, in
some cases increasing doses translated into major activity
[24–27]. Furthermore, dose titration revealed active also on
symptoms and hormone levels [28] (Table 1).
Standard dose of octreotide varies from 0.1 to 0.3 mg/day,
to be administered s.c. 2–3 times daily. High dose is more than
3 mg/day. In order to avoid multiple daily s.c. injections, a
long-acting-release (LAR) formulation was introduced, with 10,
20, and 30 mg i.m. vials to be administered every four weeks
[29]. These new forms were as active as the subcutaneous
one [30]. Lanreotide is usually administered i.m. once every 4 to
6 weeks, through a recent prolonged release formulation of 60,
90 or 120 mg (Autogel) [31].
mechanism of action
In carcinoid tumors subtype 2 and 5 sst-receptors are expressed
in the majority of cases. Octreotide showed the highest binding
affinity to the subtype 2 [32], which makes this receptor highly
probable to mediate the clinical effects of octreotide therapy in
GEP NETs. The sstr binding activates multiple intracellular
mechanisms, such as the adenylate cyclase activity inhibition,
with an inhibitory effect on secretion processes [33].
The antiproliferative effect of sst-analogs can be due to several
mechanisms, including inhibition of growth factor effects on
tumor cells, induction of apoptosis at high dose [34], and
inhibition of angiogenesis [35].
interferon
background
a-Interferon was introduced by Oberg et al. for the treatment of
carcinoid tumors in 1982 [36]. Six out of nine patients with
small intestine carcinoid and carcinoid syndrome responded
to leukocyte interferon 3 M IU per day during the first month
and 6 M IU per day for another two months. Reduction of
symptoms and amine levels, without effect on the tumor
growth, was observed. Since then, several studies were published
reporting 40–70% of symptomatic, 40–50% biochemical, and
10–15% antiproliferative activities [37–40]. The methods of
response evaluation probably underestimate the activity,
because some reports show a reduction in tumor cells
and increase in connective tissue component without any
change of the tumor on CT-scan in liver metastases from NET
patients treated with IFN [41].
Dose and schedule varied from 3 M IU s.c. three times a week
to 9 M IU s.c. daily (Table 2). The dose has to be individually
titrated. IFN-a is the most evaluated of all the IFNs in the
treatment of NETs. Nevertheless, a very recent study reported
that the antitumor activity of IFN-b in human pancreatic
carcinoid BON cell lines is considerably more potent than IFN-a
[42]. Polyethylene glycol-modified (pegylated) interferons are
long-acting formulations of IFN-a. They are administered at
doses of 50–150 lg per week, s.c.
mechanism of action
Interferons represent a large class of agents with anti-viral
and anti-tumor activity [43]. They are divided into two
groups: type I and type II. Type-I IFNs include IFN-a (leukocyte
IFN), IFN-b (fibroblast IFN), as well as IFN-w and IFN-t.
The only type-II IFN (immune IFN) is named IFN. IFN-a is
the most evaluated type of IFN in the treatment of NETs, and
acts through specific receptors on the cell surface activating
cytoplasmic messengers, such as Janus kinase 1 (JAK-1) and
Tyrosine kinase 2 (TYK-2). The action of IFN derives from
a direct effect on the cell cycle, inducing the arrest in G1 and
G0 [44], an inhibition of growth factors production, a class 1
antigens induction on the cell surface therefore activating the
immune response, and an anti-angiogenic effect [45].
medical treatment
The medical treatment of GEP NETs is based on the biological
and clinical characteristics of the tumor. Chemotherapy,
interferon-a, and sst-analogs represent the three possible
systemic therapeutical options. Chemotherapy is indicated in
two subgroups: poorly-differentiated NETs or NETs with
rapid clinical progression, that respond to a combination of
Table 1. NETs sst-analog treatment
Response Standard dose (%)
100–1500 mg/d
High dose (%)
>3 mg/d
SR (%) 20–30 mg/
2–4w
Subjective 64 42 63
Biochemical 63 75 67
Tumor 5 13 3
Table 2. NETs IFN-a treatment
Response Regular dose High dose
3–6 MU · 3–7/w 24 MU/m2 · 3/w
Subjective 53 32
Biochemical 49 39
Tumor 12 20
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cisplatin and etoposide [46], and pancreatic endocrine
carcinomas, in which streptozotocin-based chemotherapy has
been proven active [47].
In well-differentiated and slow-growing tumors, biotherapy
is preferred to chemotherapy. If sst-receptors are expressed,
a sst-analog should be proposed in functioning and in
progressive, metastatic disease, even without the syndrome [48].
If sst-receptors are negative IFN-a is indicated in functioning or
progressive disease. In metastatic, sstr-negative, IFN-a-resistant
GEP NETs a shift to chemotherapy can be evaluated. In sstr-
positive diseases resistant to sst-analog, a dose-escalation of
the analog or the addition of IFN-a is usually applied, in
particular in functioning diseases. However, the withdrawal
of the analog and its substitution with IFN-a can be considered
in non-functioning, sstr-positive diseases.
Therefore, some settings exist in which the two forms of
biotherapy, sst-analog and IFN-a, are used together. This
prompted some authors to study whether the combination is
better than the single-agent use. In this review we analyze the
non-randomized and randomized trials that addressed this topic.
non-randomized trials
The combination of IFN-a and sst-analogs has been studied in
some non-randomized trials (Table 3).
However, the first evidence of some activity due to the
combination of interferon and octreotide, rather than the same
drugs used as single agent, appeared as a case report by Joensuu
in 1992 [49]. A 43-year-old man with several symptoms due to
a retroperitoneal unknown-primary NET, who had been
receiving IFN-a-2b, 10 M IU s.c. three times a week, with
incomplete symptom control, benefited from the addition of
octreotide 0.1 mg twice daily (b.i.d.) subcutaneoulsy. Symptoms
totally disappeared and both tended to reappear when
octreotide was reduced to 0.05 mg b.i.d. and IFN was gradually
withdrawn. In both cases symptoms disappeared when
octreotide dose was increased again and interferon resumed.
In the same year Janson et al. [50] reported the efficacy of
interferon/octreotide combination in 24 NET patients clinically
progressive to octreotide alone. Patient population was quite
homogeneous, with 23 of 24 having a mid-gut carcinoid and
18 of 24 showing a carcinoid syndrome. All patients had a
biochemical progression after having received octreotide for a
median time of eight months. Ten of them initially responded to
the regular dose (0.05–0.1 mg twice a day), but then did not
respond to the dose escalation (up to a median of 0.3 mg/day).
The other 14 showed symptomatic or biochemical progression
just after three months of octreotide. IFN-a addition, with
a median s.c. dose of 9 M IU/week, produced a 77% of
biochemical response rate, lasting for a median of 12 months
(range 5–46). Nine of the 17 responding patients had previously
been treated with IFN-a 9 M IU/week but were progressive or
intolerant, leading one to suppose that the combination is better
not only for efficacy but also for tolerability. The authors stated
that the benefit is due to the combination and not to IFN alone,
because the known biochemical response rate of IFN-a alone
is 44% and an increase of biochemical markers occurred
when IFN was withdrawn. However, noWHO partial responses,
but only four stable diseases, were obtained. Considering that,
four out of five patients showing an increase in tumor size and
had a concurrent biochemical response (> 50% decrease of
HIAA urinary level), it is difficult to understand the clinical
meaning of the biochemical markers behavior. However, of the
18 patients presenting with the carcinoid syndrome three had
a complete relief of all their symptoms and/or signs, while five
obtained a complete relief of one of the symptoms,
demonstrating that the addition of IFN-a is effective on
symptom control. The reappearance of symptoms and re-
increasing of HIAA in each of the eight patients where IFN-a
was withdrawn, and the effective re-introduction of IFN-a in
three of these patients, showed the benefit of the combination
rather than the single agents. Toxicity increased with IFN-a,
including temporary flu-like symptoms, tiredness, anorexia,
dryness of skin, leukopenia, and thrombocytopenia, but no side
effects caused clinical complications or induced definitive drug
withdrawal. Finally, it is not possible to draw any conclusion
about the anti-tumor activity of the IFN addition, because the
radiological status of the disease at the beginning of the therapy
in the 15 patients who showed stable disease with IFN-a
addition has not been specified.
Another trial was conducted by Frank and co-workers [51] on
21 patients with metastatic GEP NET. In this study the
population was less homogeneous than Janson’s, including nine
patients with carcinoid syndrome, eight with non-functioning
pancreatic NET, and four with gastrinoma. Nevertheless, unlike
Janson’s study, all patients had CT-documented tumor
progression before entering the study. All patients received the
combination of octreotide 0.2 mg three times daily (t.i.d.) and
IFN-a 5 M IU three times a week. Sixteen patients had already
been treated with octreotide 0.2 mg t.i.d. An inhibition of
tumour growth was obtained in 67% (14/21) of patients, lasting
for more than three months. Thirteen patients had WHO stable
disease, for a median of 12 months (range 3–52), and one had
a hepatic WHO complete response (lasting for four years). Also
this study showed that biochemical response does not correlate
to the inhibition of tumour growth. Although this was not
a phase-III trial, the authors underlined in the discussion that
responders had a significantly longer survival (median, 68
months) than non responders (median, 23 months). Interferon-
related side effects were more severe than those attributable to
octreotide; however, general toxicity was mild and did not
Table 3. IFN-a/sst-analog combination therapy: published non
randomized trials
Author No. pts Subjective
(%) resp. pts
Biochemical
(%) resp. pts
Radiological
resp. pts
Janson, 1992 24 10/18 (55) 17/22 (77) 15 SD
Frank, 1999 21 NR 9/13 (69) 14 SD
1 CR
Fjallskog, 2002 16 NR 10/16 (63) 11 SD
3 PR
Artale, 2005 11 3/4 (75) 6/9 (66) 7 SD
4 PR
Pavel, 2006* 17 NR 6/15 (40) 11 SD
2 PR
*With PEG-IFN.
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require dose reduction. Only two patients refused further
treatment after four months of therapy despite stabilization of
tumor growth, because of interferon-induced flu-like side effects.
Three out of 20 patients who underwent octreoscan did not
express sstr-2 and -5 receptors. However, all but one responding
patients had a positive octreoscan. Also five out of seven non-
responders had a positive octreoscan. Unfortunately, it is not
possible to draw any clinical conclusion from these data,
regarding the possible predictive role of sst-receptors. It remains
unexplained why patients with a negative octreoscan received an
sst-analog. While the Janson’s study showed the better
symptomatic effect of the combination on the single agent
therapy, the Frank’s one showed the better antiproliferative
activity.
The third non-randomized trial was published in 2002, by
Fja¨llskog et al. from the Uppsala group [52]. It reported the
results of IFN + octreotide or lanreotide in 16 patients with
metastatic pancreatic endocrine tumors, eight of which were
non-functioning. Doses of IFN-a and sst-analog were
individually titrated, IFN varying between 9 and 25 MU/week
and octreotide and lanreotide at a dose of 0.1–1.5 mg and 6 mg
daily, respectively. Eight of 16 patients had previously received
IFN alone, six analog alone, and seven IFN or analog plus
chemotherapy. All patients were defined as progressing when
starting the new treatment, but the kind of progression,
radiological or biochemical, is not specified. A partial response
(PR), according to the WHO criteria, was seen in three patients
(19%), with a median duration of 23 months (range 19–25),
and a stable disease (SD) in 11 patients (69%), with a median
duration of 13 months (range 4–32). Among the eight patients
previously progressing on IFN alone, one PR and five SD were
obtained; whereas all patients previously progressing on sst-
analog showed a SD. The biochemical response rate was 38%
among IFN-progressing patients and 33% among sst-analog
patients. All three patients previously progressing on both IFN
and sst-analog as single drug achieved a biochemical and
radiological stabilization of the disease with the combination.
All side effects were mild except for two patients experiencing
grade 3 cortical neurological toxicity. The authors conclude that
the combination of IFN and sst-analog can be proposed to
patients progressing on single treatment with IFN or sst-analog
or to patients who fail during chemotherapy. However, the
radiological response evaluation is suboptimal in this study,
considering that two patients were only examined with
ultrasonography and in two other patients CT examinations
were misplaced. Furthermore, toxicity should be considered as
a possible factor limiting the feasibility, at least at some doses
of IFN, given that three of 16 patients ended the treatment
because of grade 2–3 side effects. Nevertheless, this is the only
one out of the three non-randomized trials that showed some
activity data of the combination in patients progressing to IFN-a.
All three studies above led to suggest a better activity
for the combination than for single-agent therapy.
A recently published Italian experience [53] strengthens this
concept. Interferon-a 5 MU · 3/w plus LAR octreotide 30 mg
q4w, were administered in 11 patients, four of whompre-treated,
with well-differentiated NETs. The obtained rate of PR (36%) is
higher than known from literature for IFN or octreotide as single
agent, and suggests a synergic or additive effect of combination.
Unfortunately, higher toxicity of the combination remains
a concern. However, we did not observe significant toxicity
with lower doses of IFN [54]. At the European Institute of
Oncology we treated 16 well-differentiated NETs patients (12 of
whom were pre-treated) with IFN-a 1 MU a day over 5 days/
week plus LAR octreotide 20 mg q4w. No G2-4 toxicity was
seen, in particular no flu-like syndrome. Notably, two PR and
two SD (in previously progressive patients) were obtained
(25%) (unpublished data). On the other hand, we did not find
any correlation between blood levels of Vascular Endothelial
Growth Factor (VEGF) and basic Fibroblast Growth Factor
(bFGF) and clinical behavior, even though an antiangiogenic
activity of low and protracted doses of IFN-a has been reported
in preclinical studies [55].
Further interesting results in terms of activity and low toxicity
of the combination come from a very recent published
experience with PEG-IFN. In 17 patients with well-
differentiated metastatic GEP NETs treated with LAR
octreotide, PEG-Interferon-a in 11 and IFN-a in 6 were added
3–108 months after initiation of octreotide therapy. IFN-a
was added at a dose of 5 MU thrice weekly, but treatment
was stopped in all six patients because of severe side effects.
At further progression PEG-IFN was added. PEG-IFN was given
at a dose of 50–100 lg/week s.c. Partial regression was
observed in two patients and stable disease in 11. The median
duration of response was 12 months [56].
randomized trials
A randomized trial was conducted by Kolby et al., to study
the effect of IFN-a addition to octreotide on survival [57].
Sixty-eight patients with metastatic mid-gut carcinoid were
included in 10 centers between 1991 and 1998 (Table 4). All
patients had been operated on their primary tumors and treated
with hepatic trans-arterial embolization (TAE) before having
been randomized to either octreotide or a combination of
octreotide and IFN-a. At the time of randomization all patients
Table 4. IFN-a/sst-analog combination therapy: published randomized
trials
Author No. pts Arms Results
5-year-survey (%)
Ko¨lby 2003 68 IFNa 36.6
1991–98 OCT+IFNa 56.8
HR 0.62 (CI 95% = 0.3–1.1)
P = 0.132
1-year PFS (%)
Faiss 2003 80 IFNa 44.4
1995–98 LAN 44
IFNa+LAN 50 p = 0.69
Median survival (months)
Arnold 2005 109 OCT 35
1995–98 OCT+IFNa 51
HR 1.19 (CI 95% = 0.67–2.13)
P = 0.55
LAN, lanreotide; OCT, octreotide; IFN, interferon; HR, hazard ratio
PFS, progression free survival.
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had liver metastases. Patients received octreotide 0.1 mg b.i.d.,
increased to 0.2 mg t.i.d. in case of persistent carcinoid
symptoms. The IFN started with 3 MU · 3/week and was
increased to a maximal dose of 5 MU · 5/week. The study
endpoints were death, progressive tumor growth (more than
25% of increase at CT or ultrasonography, or more than 25% of
HIAA level increase, or new metastases), or life-threatening
side-effects of the treatment. An overall five-year survival rate of
46.5% during a follow-up period of 33–120 months was
obtained. No statistically significant difference in survival
between the two groups resulted, even though in the
combination group 5-year survival was longer than in the
octreotide group (56.8 % and 36.6 % respectively; P = 0.132). As
for risk of tumor progression, patients treated with octreotide
and IFN-a had a significantly lower risk of progressive disease
(HR 0.28, 95% CI 30.16–0.45; P = 0.008). Of the 25 patients
reported to have tumor progression, 19 were treated with
octreotide alone compared to six who received the combination.
Toxicity was relatively equivalent between the two groups, even
though the only severe side effect occurred in the combination
arm. The authors reported two statistical considerations. One is
that the statistical power of this study is too low to lead to any
definitive conclusion, considering that 230 patients would be
required in each group to give an 80% probability of achieving
a statistically significant difference in survival. The other is that
the lack of a blinded design could have overestimated the
prolongation of the progression free interval by IFN-a.
The second randomized trial was published in July 2003, in
the Journal of Clinical Oncology, by Faiss et al. [58], and was
a three-arm trial. Between 1995 and 1998, 84 untreated patients
with CT- or US-documented progressive well-differentiated
metastatic NETs were randomized to lanreotide 1 mg s.c.
t.i.d., IFN-a 5 MU s.c. · 3/week, or a combination of the two
drugs at the same doses. The main objective of this study was the
1-year (1-y) progression-free survival (PFS) rate. Sample-size
calculations were based on the hypothesis that 1-y PFS rate of
patients with metastatic NETs treated with IFN is lower (15%)
than the corresponding rate of patients with lanreotide (25%)
and that the combination of the two drugs (45%) is superior to
the corresponding monotherapies. The population of patients
was quite heterogeneous, and most diseases were non-
functioning. Although there were more PRs in the combination
arm compared to the single agent arms (two, one, and one,
respectively), no significant difference in rates of PR, SD and
progressive disease (PD) between the three arms was recorded.
Partial response rate was 4%, 3.7%, and 7.1%, and SD rate 28%,
25.9%, and 17.9%, for lanreotide, IFN-a, and combination
group, respectively. Within 1 year of therapy, tumor progression
was observed in 56% of patients in the lanreotide arm, 55% in
the IFN-a arm, and 50% in the combination arm, without
a statistically significant difference. However, one of the 11
patients progressed on lanreotide and shifted to the combination
showed a clear reduction in the rate of tumor growth.
Furthermore, a statistically significant reduction of symptoms
was only observed in the combination arm (P = 0.037, Wilcoxon
test). Biochemical response did not differ among the treatment
groups, and this study showed once again that it was not
correlated with inhibition of tumor growth. Combination
therapy seemed to be more toxic than monotherapy with seven
of 28 patients who had to stop treatment compared to 4 of 27 in
the IFN arm and 3 of 25 in the lanreotide arm. However,
difference in time in study between the three arms was not
statistically significant (P = 0.337, Kruskal-Wallis test).
Some criticisms were moved to this study, not completely
clarified by the authors’ reply. We [59] remarked that in this
study it is not clear if all patients were evaluated by CT-scan, as
requested by the WHO. As a matter of fact, this is a drawback
found also in Fjiallskog’s, Ko¨lby’s, and Janson’s trials.
Unfortunately, ultrasound is a very operator-dependent
examination and therefore it should not be used alone for
response evaluation. Considering the very low PR rate in NETs,
even very small differences can be crucial to conclude for the
activity of some drugs, and therefore the less subjective
examination should be used to evaluate the response, all patients
undergoing the same kind of examination. Other criticisms [60]
regarded the statistical aspects of this study. In particular, it was
closed after 80 patients instead of the 105 planned patients.
Furthermore, it is not clear on what the authors based their
assumption of a 15% of PFS at one year for IFN and 25% for
lanreotide. Finally, heterogeneity of patients and lack of
optimization of treatment were other points of criticisms.
The third randomized trial, by Arnold et al. [61], has been
recently published in Clinical Gastroenterology and Hepatology.
Between January 1995 and March 1998 109 patients with
advanced GEP NETs were randomized to octreotide 0.2 mg
t.i.d. ± IFN-a 4.5 MU · 3/week. The dose of IFN was adapted to
strategies in hepatitis B before pegylate interferons had been
introduced. Population was quite homogeneous, pancreatic and
midgut NETs representing the main group. Carcinoid syndrome
was present in 40% of patients. Surprisingly, 45% of patients,
fairly distributed in the two groups, had negative or
unperformed octreoscan. Unlike previous studies, only patients
with CT-scan or MRI documented tumor progression were
included. Pre-treatment with IFN was an exclusion criteria,
whereas octreotide £ 150 lg per day against carcinoid syndrome
was allowed. Although median survival was longer in the
combination arm (51 versus 35 months) the hazard ratio of 0.82
(95% CI 0.52–1.29) and P = 0.38 concluded for a non-
statistically significant advantage. The Kaplan-Meier plot for
long-term survival described an advantage for patients in the
combination arm of between 24 and 84 months. However, the
study population was too small to prove statistically a survival
advantage of the combination arm for long-term survival. Time
to treatment failure, that was the primary endpoint of this study,
was similar between the two arms within six months and slightly
better but not statistically significant in the combination arm
after six months. Also radiological, biochemical and subjective
responses were not significantly different between the two
groups. Notably, a partial regression was more frequent at
month 12 in the combination arm, arguing a possible late effect
on the tumor growth. Patients with slowly growing (TTP > 6
months) tumors prior to treatment and those with low Ki67 had
a survival advantage compared with patients with a more rapid
progression and higher Ki67. Adverse events were more frequent
in the combination arm, which resulted in discontinuation of
treatment in 11 of 54 patients, unlike the monotherapy arm with
two of 51. Likewise, quality of life after 3 months of
treatment was lower in the combination than in the
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monotherapy arm (56.3 ± 23.4 versus 69.3 ± 14.6; P = 0.039).
This study showed for the first time that response with
stabilization or partial regression to octreotide or octreotide
plus interferon-a affects survival favorably.
From the above described randomized trials, a non-
statistically significant advantage in terms of survival for the
combination comes out. Furthermore, all three studies were too
small to show a statistically significant advantage.
Unfortunately, this is not enough to use the combination as an
upfront treatment.
conclusion
Clinical trials studying the efficacy of IFN-a combined with
sst-analog in patients with NETs are supported by some in vitro
and in vivo evidence.
Interferon produces an up-regulation of somatostatin
receptors in vitro [62]. The two cyclin-dependent kinase
inhibitors p21 and p27 involved in the cell-cycle block in the
G2-S phase induced by IFN [63, 64], can be up-regulated by
somatostatin analogs [65]. Reduction in growth factors and
their receptors as well as antiangiogenic activity can be effected
by both drugs. Finally, IFN and sst-analog in combination
showed a stronger antiproliferative effect than either drug alone,
in an in vivo model with xenografted BON cells [66].
Nevertheless, it has not yet been clearly defined whether the
combined use of IFN-a and sst-analog is clinically more
effective than the use of the same drugs as a single agent. Some
non-randomized studies indicate that there is an additive effect
of the combination, but the only three randomized trials
published so far did not show any statistically-significant
differences in terms of survival because of their different design
and low statistical power.
Furthermore, the combination seems to be more toxic than
monotherapy, at least at 3 MU · 3/week or more of IFN. Lower
dose of IFN showed to be active in combination with analog and
therefore should further be studied in randomized trials.
At present we do not have enough statistical evidence for an
upfront use of the combination of IFN-a and sst-analog in
patients with NETs, but we have some clinical evidence coming
from non-randomized studies and the sub-analysis of
randomized trials, that would justify the sequential use of the
two drugs or the combination after progression to single agent
therapy.
To have a conclusive response, larger clinical trials in
international, prospective, randomized, multicentric settings
studying a homogeneous population are necessary, possibly
with a placebo arm, even though the rarity and heterogeneity of
this malignancy makes this aim very difficult.
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